Antibody-Drug Conjugates (ADCs) are revolutionizing targeted therapies. By combining the specificity of a monoclonal antibody with the potency of a cytotoxic drug, they offer highly targeted treatments. However, this hybrid nature makes ADC analysis exceptionally complex. To help biopharmaceutical companies navigate these analytical challenges, the experts at FILAB Laboratory answer your key questions.
ADC Analysis: key questions & answers
What makes ADC characterization more complex than traditional biologics?
Unlike standard monoclonal antibodies (mAbs), ADCs consist of three distinct components: the antibody, the linker, and the cytotoxic payload.
This structural complexity creates high heterogeneity. Analytical methods must not only characterize the intact protein but also assess the small-molecule drug, the stability of the linker, and the distribution of the drug molecules on the antibody.
Standard biopharmaceutical testing is simply not enough; it requires specialized, multi-disciplinary analytical expertise.
At FILAB, we perform comprehensive structural confirmation of ADCs combining high-resolution mass spectrometry (HPLC-HRMS), peptide mapping, and orthogonal physicochemical techniques to ensure full molecular understanding.
Our approach covers primary sequence confirmation (peptide mapping and de novo sequencing), intact mass determination, disulfide bridge characterization, and higher-order structure evaluation (FTIR, Circular Dichroism, DSC).
This multi-level strategy allows precise control of Critical Quality Attributes (CQAs) required for CMC development.
What is the Drug-to-Antibody Ratio (DAR) ?
Drug-to-Antibody Ratio (DAR)
To accurately determine both the average DAR and the drug load distribution.
We resolve the different DAR species and accurately determine the average DAR value.
Allows evaluation of heterogeneity associated with conjugation.
Provides absolute molecular weight determination and aggregation monitoring, strengthening DAR interpretation.
How do you evaluate ADC heterogeneity?
ADC conjugation introduces structural variants that must be precisely characterized. FILAB provides in-depth heterogeneity profiling including:
Aggregation analysis by Size Exclusion Chromatography (SEC)
Post-Translational Modifications (PTMs) identification and quantification by HPLC-HRMS/MS (deamidation, oxidation, glycosylation)...
Charge variants profiling by Ion Exchange Chromatography (IEX-UV)
Fragment characterization (HC, LC, Fab, Fc forms)
We also characterize glycosylation patterns, including carbohydrate structure elucidation, monosaccharide composition, and glycosylation site identification. This detailed profiling ensures product consistency and comparability during development.
How do you assess ADC stability?
ADCs are sensitive to thermal, chemical, and oxidative stress, which may induce aggregation, fragmentation, deconjugation, or structural modification. At FILAB, we implement stability-indicating methods including:
Forced degradation studies (thermal, oxidative, pH stress) are performed to identify degradation pathways and evaluate linker robustness. We also quantify potential released payload and small-molecule related impurities using dedicated LC-MS methods.
What impurities and contaminants must be monitored in ADCs?
ADC manufacturing introduces both biologic and small-molecule related impurities. FILAB supports impurity profiling including:
Process-related impurities:
Host Cell Proteins (HCP) detection and quantification
Residual DNA analysis
Extractables & Leachables (E&L) studies
Residual solvents and culture media components (amino acids, vitamins, saccharides)
Product-related impurities:
Aggregates
Fragments
Oxidized or deamidated forms
Free payload traces
This dual expertise in biologics and small molecules is essential for ADC quality control.
Why choose FILAB Laboratory for your ADC analytical outsourcing?
Developing an ADC requires an agile, highly equipped, and experienced analytical partner. FILAB Laboratory offers:
State-of-the-art equipment: High-resolution LC-MS, SEC-HPLC, and CE systems.
Custom method development: We design and validate analytical methods tailored to your specific linker-payload technology.
Cross-functional expertise: Bridging the gap between large molecule characterization and small molecule impurity analysis.
Full physico-chemical characterization packages adapted to CMC requirements.
Stability-indicating method development and validation according to ICH guidelines.
Support for batch comparability studies and process optimization.
GMP-compliant analytical environment for regulated studies.
Ready to advance your ADC development? Do not let analytical bottlenecks slow down your pipeline. Contact FILAB Laboratory to discuss your analytical needs with our biopharmaceutical experts.
Laboratoire d’analyses et d’expertises spécialisé pour les industriels
